Cytoplatin Injection
Cytoplatin (Cisplatin 50 mg) — Cipla platinum-based DNA cross-linker for solid tumours. Mandatory hyperhydration and electrolyte replacement protocols.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
Quick Answer
Cytoplatin Injection — Cisplatin (Cipla Inc). Platinum-based DNA cross-linking chemotherapy. Platinum-based DNA cross-linking agent for solid tumours. Mandatory hyperhydration protocol. Hospital-administered IV. Strict pre-medication, hydration, and antiemetic protocols.
What you get with MedsBase:
- WHO-GMP certified manufacturer
- Discreet plain-envelope packaging
- Worldwide shipping
- Rated by 1,400+ customers (read reviews)
📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.
Why order from MedsBase
Cytoplatin Injection ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
All platinum agents are hospital-administered intravenous chemotherapy under specialist supervision. Self-administration is not appropriate. Pre-medication, hydration, antiemetic regimens, and monitoring are part of the protocol.
Cisplatin: nephrotoxicity (mandatory hyperhydration), severe nausea/vomiting, ototoxicity (especially in children — pre/post audiometry), peripheral neuropathy, electrolyte wasting (Mg, K). Oxaliplatin: cumulative peripheral neuropathy (cold-triggered acute neuropathy is distinctive), less nephrotoxic, less emetogenic. Carboplatin: dose-limiting myelosuppression, AUC-based dosing (Calvert formula).
Frequently Asked Questions
When is platinum chemotherapy used?
Cisplatin: testicular, ovarian, lung, bladder, head and neck, cervical cancers. Oxaliplatin: colorectal cancer (FOLFOX, CAPEOX). Carboplatin: ovarian, lung, breast, head and neck — typically when cisplatin toxicity profile is unacceptable.
How is it given?
IV infusion in a chemotherapy day-unit. Pre-medication includes antiemetics (5-HT3 antagonist + dexamethasone + NK1 antagonist), IV fluids (cisplatin requires aggressive hydration). Each cycle is 2-4 weeks depending on regimen.
Side effects to expect?
Nausea/vomiting (managed with antiemetics), fatigue, neutropenia, thrombocytopenia, neuropathy (oxaliplatin especially), tinnitus/hearing loss (cisplatin), renal dysfunction (cisplatin).
Pre-medication?
Antiemetics: ondansetron + dexamethasone + (for highly emetogenic regimens) aprepitant. Hydration: 1-3 L of saline before/after cisplatin.
Renal monitoring?
Cisplatin: baseline + before each cycle + weekly during therapy. Stop or switch if creatinine rises >25% from baseline. Magnesium and potassium replacement common.
Hearing test?
Audiometry baseline and as clinically indicated for cisplatin (especially in paediatric, repeated cycles, or pre-existing hearing loss).
Pregnancy?
Strongly contraindicated — teratogenic and abortifacient. Effective contraception during and for ≥6 months after for both partners.
Drug interactions?
Aminoglycosides + cisplatin: massive nephrotoxicity. NSAIDs + cisplatin: nephrotoxicity. Phenytoin levels may drop with platinum chemo. Always disclose all medications.
Cumulative dose limits?
Cisplatin: stop or switch at cumulative neurotoxicity, ototoxicity, or persistent renal impairment. Oxaliplatin: total dose 850 mg/m² is associated with cumulative neuropathy — protocols typically include planned breaks (FOLFOX 4-6, then re-introduction).
When is treatment stopped?
Tumour response/disease progression dictates duration. Specialist decision based on response evaluation criteria (RECIST), toxicity, and patient goals.
Other Cancer Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
More options in Anti Cancer Medication
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 50 mg |
|---|---|
| Quantity | 1 Vial/s, 3 Vial/s, 6 Vial/s |
| Pharma Form | Vials/s |
| Manufacturer | Cipla Inc |
| Treatment | Lung cancer, Ovarian cancer, Cervical cancer |
| Generic Brand | Cisplatin |
Cytoplatin Injection
Q & A
Cytoplatin Injection
Related products
Reviews
There are no reviews yet